黄维-mile米乐体育

官方微信
手机版

中药化学方向

黄维

 

 

f5af3986a678447d8cdb5950f0010a69.jpeg

 

 

黄维,医学博士/博士后,教授,博士研究生导师。四川省杰出青年资助计划,世界中医药学会联合会“中药上市后再评价专业委员会”委员,四川省第二届药品安全专家委员会委员秘书

研究方向:中药活性成分机制及构效关系研究;结合中药多成分、多靶点协同作用特点,融合生物信息学、网络药理学、系统毒理学、手性合成、计算化学等多学科手段,研究中药药效物质作用机制及构效关系。

目前作为负责人,主持国家自然科学基金面上项目3项、国家自然科学基金青年基金、四川省重点研发项目、四川省杰出青年基金、中国博士后科学基金特别资助项目、中国博士后科学基金面上项目(一等)、教育部博士点基金、四川省科技厅基础项目等课题;相关成果发表在chemical communications; organic chemistry frontiers; acta pharmaceutica sinica b; advanced synthesis & catalysis等国内外学术期刊上,共计收录八十余篇,其中以第一作者或通讯作者发表sci论文43篇;获得国家授权发明专利7项;教材编撰8部,包括“十五”“十三五”规划教材《药物化学》、“十三五”规划教材《天然药物化学》

获四川省科技进步一等奖。入选首届成都中医药大学“天府学者”学术荣誉体系:青年英才;入选第十三批四川省学术和技术带头人后备人选;指导学生参加教育部高等学校第九届国际大学生“药苑论坛”:获创新成果奖、优秀墙报奖;指导的研究生多次获得国家奖学金学业奖学金等荣誉

 

m6米乐安卓版下载的联系方式:huangwei@cdutcm.edu.cn 

 

主持基金项目:

1.国家自然科学基金面上项目,钩藤吲哚生物碱诱导线粒体自噬治疗pd的分子网络机制和立体异构效应研究,2021/01/-2024/12,55万元,负责人

2.国家自然科学基金面上项目,以配位化学关联手性结构特征探究中药熟地黄通过自噬-溶酶体途径治疗帕金森病的物质基础,2018/01-2021/12,55万元,负责人

3.国家自然科学基金面上项目,融合多层次化学结构特征研究钩吻中吲哚生物碱抗乳腺癌的构效关系和作用机制,2016/01-2019/12,57万元,负责人

4.国家自然科学基金青年项目,基于多靶标网络调控研究青黛治疗慢粒白血病的药效物质基础和作用机制,2014/01-2016/12,23万元,负责人

5.四川省重点研发项目,中药调控细胞程序性死亡的活性物质库构建和成药性评价,2021/04-2023/03,100万元,负责人

6.成都中医药大学“杏林学者”学科人才创新团队,中药调控细胞程序性死亡的活性物质库构建及创新药物设计开发2022/9-2025/9100万元,负责人

 

代表性成果:

1.chen, b.-h.; liu, s.-j.; zhao, q.; hou, q.; yuan, j.-l.; zhan, g.; yang, q.-q.; huang, w.*, palladium-catalyzed asymmetric 4 2 annulation of vinyl benzoxazinanones with pyrazolone 4,5-diones to access spirobenzoxazine frameworks. chemical communications 2023, 59 (9), 1233-1236. 中科院二区if:6.065

2.tang, j.; yan, z.-h.; zhan, g.; yang, q.-q.; cheng, y.-y.; li, x.; huang, w.*, visible-light-mediated sequential wolff rearrangement and staudinger cycloaddition enabling the assembly of spiro-pyrazolone-beta-lactams. organic chemistry frontiers 2022, 9 (16), 4341-4346. 中科院一区if: 5.456

3.wang, y.; he, m.; li, x.; chai, j.; jiang, q.; peng, c.; he, g.; huang, w.*, design, synthesis, and biological evaluation of pyrano 2,3-c -pyrazole-based rala inhibitors against hepatocellular carcinoma. frontiers in chemistry 2021, 9, 700956. 中科院二区if: 5.545

4.li, c.; zuo, w.-f.; zhou, j.; zhou, w.-j.; wang, m.; li, x.; zhan, g.; huang, w.*, catalytic asymmetric synthesis of 3,4 '-indole-pyrazole derivatives featuring axially chiral bis-pentatomic heteroaryls. organic chemistry frontiers 2022, 9 (7), 1808-1813. 中科院一区if: 5.456

5.qin, r.; yu, t.-t.; liu, s.-j.; wang, y.-c.; luo, m.-l.; chen, b.-h.; zhao, q.; huang, w., asymmetric 4 2 annulation of cyclobutenones and pyrazolone 4,5-diones: access to novel delta-lactone-fused spiropyrazolones. journal of organic chemistry 2022, 87 (8), 5358-5370. 中科院二区if: 4.198

6.qin, r.; zhao, q.; han, b.; zhu, h.-p.; peng, c.; zhan, g.; huang, w.*, indole-based small molecules as potential therapeutic agents for the treatment of fibrosis. frontiers in pharmacology 2022, 13, 845892. 中科院二区if: 5.988

7.zhao, y.; he, g.; huang, w.*, a novel model of molnupiravir against sars-cov-2 replication: accumulated rna mutations to induce error catastrophe. signal transduction and targeted therapy 2021, 6 (1), 410. 中科院一区,if: 38.104

8.ye, c.; zhang, n.; zhao, q.; xie, x.; li, x.; zhu, h.-p.; peng, c.; huang, w.*; han, b., evodiamine alleviates lipopolysaccharide-induced pulmonary inflammation and fibrosis by activating apelin pathway. phytotherapy research 2021, 35 (6), 3406-3417. 中科院二区if: 6.388

9.tang, x.; wu, y.; jiang, j.; fang, h.; zhou, w.-j.; huang, w.*; zhan, g., formal (3 1 1) carboannulation of morita-baylis-hillman carbonates with pyridinium ylides: access to spiro-cyclopentadiene oxindoles. organic letters 2021, 23 (22), 8937-8941. 中科院一区if: 6.072

10.mu, j.; xie, x.; xiong, s.; zhang, y.; wang, y.; zhao, q.; zhu, h.; huang, w.*; he, g., discovery of spirooxindole-ferrocene hybrids as novel mdm2 inhibitors. chinese chemical letters 2021, 32 (6), 1897-1901. 中科院二区if: 8.455

11.leng, h.; zhao, q.; mao, q.; liu, s.; luo, m.; qin, r.; huang, w.*; zhan, g., nhc-catalysed retro-aldol/aldol cascade reaction enabling solvent-controlled stereodivergent synthesis of spirooxindoles. chinese chemical letters 2021, 32 (8), 2567-2571. 中科院二区if: 8.455

12.zhao, q.; zhu, h.-p.; xie, x.; mao, q.; liu, y.-q.; he, x.-h.; peng, c.; jiang, q.-l.; huang, w.*, novel hsp90-pi3k dual inhibitor suppresses melanoma cell proliferation by interfering with hsp90-egfr interaction and downstream signaling pathways. international journal of molecular sciences 2020, 21 (5). 中科院二区if: 6.208

13.huang, h.; li, q.-z.; liu, y.-q.; leng, h.-j.; xiang, p.; dai, q.-s.; he, x.-h.; huang, w.*; li, j.-l., dearomative 4 2 annulations between 3-nitroindoles and enals through oxidative n-heterocyclic carbene catalysis. organic chemistry frontiers 2020, 7 (23), 3862-3867. 中科院一区if: 5.456

14.chen, c.; jiang, l.; zhang, m.; pan, x.; peng, c.; huang, w.*; jiang, q., isodunnianol alleviates doxorubicin-induced myocardial injury by activating protective autophagy. food & function 2019, 10 (5), 2651-2657. 中科院二区if: 6.317

15.li, j.-l.; dai, q.-s.; yang, k.-c.; liu, y.; zhang, x.; leng, h.-j.; peng, c.; huang, w.; li, q.-z., construction of azepino 2,3-b indole core via sulfur ylide mediated annulations. organic letters 2018, 20 (23), 7628-7632. 中科院一区if: 6.072

 

终审:药学院管理员
网站地图